Here are four things to know.
1. The figure marks a 21-year high for the agency, which has made greater efforts to streamline and simplify the drug approval process under FDA head Scott Gottlieb, MD.
2. Many of the new drugs were intended to treat rare diseases and types of cancers for very small patient populations.
3. The annual tally does not include Novartis, Gilead Sciences and Spark Therapeutics’ new cell and gene therapies, which were approved through a separate regulatory category.
4. Several medications slated for approval in the first quarter of 2018 actually got approved in 2017, which may slow the pace of drug approvals for this year.
More articles on supply chain:
Pfizer authorizes $10B share buyback
Two months after approval, Gilead’s ‘breakthrough’ cancer drug given to just a handful of patients
FDA launches website to improve management of antibiotic use
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
